270 related articles for article (PubMed ID: 34738628)
1. Glucose transporter‑1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells.
Shima T; Taniguchi K; Tokumaru Y; Inomata Y; Arima J; Lee SW; Takabe K; Yoshida K; Uchiyama K
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738628
[TBL] [Abstract][Full Text] [Related]
2. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
[TBL] [Abstract][Full Text] [Related]
3. Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
Zhang LY; Huang JS; Pi ZM; Yu MY
Int J Clin Exp Pathol; 2015; 8(9):11340-7. PubMed ID: 26617858
[TBL] [Abstract][Full Text] [Related]
4. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.
Fan R; Zhong J; Zheng S; Wang Z; Xu Y; Li S; Zhou J; Yuan F
Clin Exp Med; 2015 May; 15(2):137-44. PubMed ID: 24706111
[TBL] [Abstract][Full Text] [Related]
5. Influence of glucose transporter 1 activity inhibition on neuroblastoma in vitro.
Peng Y; Xing SN; Tang HY; Wang CD; Yi FP; Liu GL; Wu XM
Gene; 2019 Mar; 689():11-17. PubMed ID: 30553996
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Vitiello GA; Medina BD; Zeng S; Bowler TG; Zhang JQ; Loo JK; Param NJ; Liu M; Moral AJ; Zhao JN; Rossi F; Antonescu CR; Balachandran VP; Cross JR; DeMatteo RP
Clin Cancer Res; 2018 Feb; 24(4):972-984. PubMed ID: 29246941
[No Abstract] [Full Text] [Related]
7. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
[TBL] [Abstract][Full Text] [Related]
8. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
9. Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117.
Liu W; Fang Y; Wang XT; Liu J; Dan X; Sun LL
Asian Pac J Cancer Prev; 2014; 15(17):7037-41. PubMed ID: 25227787
[TBL] [Abstract][Full Text] [Related]
10. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
11. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
[TBL] [Abstract][Full Text] [Related]
12. The synergistic therapeutic effect of imatinib and protein kinase CK2 Inhibition correlates with PI3K-AKT activation in gastrointestinal stromal tumors.
Zhou L; Wang H; Liu H; Huang Z; Wang Z; Zhou X; Mu X
Clin Res Hepatol Gastroenterol; 2022; 46(6):101886. PubMed ID: 35183792
[TBL] [Abstract][Full Text] [Related]
13. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo.
Boichuk S; Galembikova A; Dunaev P; Micheeva E; Valeeva E; Novikova M; Khromova N; Kopnin P
Molecules; 2018 Oct; 23(10):. PubMed ID: 30326595
[TBL] [Abstract][Full Text] [Related]
14. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of Metabolic Vulnerability in Imatinib -Resistant Gastrointestinal Stromal Tumor.
Huang WK; Gao J; Chen Z; Shi H; Yuan J; Cui HL; Yeh CN; Bränström R; Larsson C; Li S; Lui WO
Cells; 2020 May; 9(6):. PubMed ID: 32466502
[TBL] [Abstract][Full Text] [Related]
16. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
[TBL] [Abstract][Full Text] [Related]
18. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2.
Zhao Y; Weng Z; Zhou X; Xu Z; Cao B; Wang B; Li J
J Transl Med; 2023 Mar; 21(1):219. PubMed ID: 36966336
[TBL] [Abstract][Full Text] [Related]
20. The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
Kinsella P; Greene LM; Bright SA; Pollock JK; Butini S; Campiani G; Bauer S; Williams DC; Zisterer DM
Invest New Drugs; 2016 Apr; 34(2):159-67. PubMed ID: 26885657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
